Načítá se...
Targeted biological therapies for Graves’ disease and thyroid associated ophthalmopathy. Focus on B cell depletion with Rituximab
Based on experience from the treatment of other autoimmune diseases and due to inherent shortcomings of the existing therapy options for Graves’ disease (GD) and thyroid associated ophthalmopathy (TAO), rituximab was recently introduced as a novel therapy option. Here we summarize the rationale for...
Uloženo v:
| Hlavní autoři: | , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2011
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4053536/ https://ncbi.nlm.nih.gov/pubmed/20455896 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2265.2010.03806.x |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|